Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential

Histopathology

Volumn 50, Issue 7, 2007, Pages 851-858

  O'Neill, C J ^a   McBride, H A ^a   Connolly, L E ^a   McCluggage, W G ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Immunohistochemistry; Leiomyoma; Leiomyosarcoma; p16; Smooth muscle tumour of uncertain malignant potential; Uterus

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MUSCLE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE; UTERUS; UTERUS MYOMA;

CELL COUNT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; NEOPLASM PROTEINS; SMOOTH MUSCLE TUMOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UTERINE NEOPLASMS;

EID: 34249822778     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02699.x     Document Type: Article

References (29)

1. Parazzini F, La Vecchia C, Negri E et al. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet. Gynecol. 1988 72 853 857.
2. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 2005 576 22 38.
3. Soufir N, Basset-Seguin N. The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis. Bull. Cancer 2001 88 1061 1067.
4. Bodner-Adler B, Bodner K, Czerwenka K et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol. Oncol. 2005 96 62 6.
5. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon : IARC Press 2003.
6. Jeffers MD, Farquharson MA, Richmond JA et al. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J. Pathol. 1995 177 65 70.
7. Peters WA, Howard DR, Andersen WA et al. Uterine smooth-muscle tumors of uncertain malignant potential. Obstet. Gynecol. 1994 83 1015 1020.
8. Esposito NN, Hunt JL, Bakker A et al. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. Am. J. Surg. Pathol. 2006 30 97 103.
9. Cho YL, Bae S, Koo MS et al. Array comparative genomic hybridization analysis of uterine leiomyosarcoma. Gynecol. Oncol. 2005 99 545 551.
10. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet. Cytogenet. 2000 121 1 8.
11. Packenham JP, du Manoir S, Schrock E et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol. Carcinogen. 1997 19 273 279.
12. Zhai YL, Nikaido T, Orii A, Horiuchi A, Toki T, Fuji S. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol. Oncol. 1999 75 453 459.
13. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Histopathology 2006 48 563 568.
14. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv. Anat. Pathol. 2006 13 8 15.
15. Blom R, Guerrieri C, Stal O et al. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol. Oncol. 1998 68 54 61.
16. Layfield LJ, Liu K, Dodge R et al. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology. Arch. Pathol. Lab. Med. 2000 124 221 227.
17. Zhai YL, Kobayashi Y, Mori A et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int. J. Gynecol. Pathol. 1999 18 20 28.
18. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum. Pathol. 2001 32 984 987.
19. Sprogoe-Jakobsen S, Holund B. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus). APMIS 1996 104 705 708.
20. Niemann TH, Raab SS, Lenel JC et al. p53 protein overexpression in smooth muscle tumors of the uterus. Hum. Pathol. 1995 26 375 379.
21. Rath-Wolfson L, Rosenblat Y, Halpern M et al. A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth muscle tumors. J. Cell Mol. Med. 2006 10 197 205.
22. Leiser AL, Anderson SE, Nonaka D et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol. Oncol. 2006 101 86 91.
23. Gannon BR, Childs TJ. Tissue microarray analysis of immunohistochemical profiles in leiomyosarcomas and leiomyomas. Abstract. Atlanta : United States and Canadian Academy of Pathology 2006.
24. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J. Pathol. 2006 208 1 6.
25. Lax SF, Kendall B, Tashiro H et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000 88 814 824.
26. Kovaler S, Marchenko ND, Gugliotta BG et al. Loss of p53 function in uterine papillary serous carcinoma. Hum. Pathol. 1998 29 613 619.
27. McCluggage WG, Connolly LE, McGregor G et al. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int. J. Gynecol. Pathol. 2005 24 307 312.
28. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int. J. Gynecol. Pathol. 1995 14 134 142.
29. Mayerhofer K, Lozanov P, Bodner K et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet. Gynecol. Scand. 2004 83 1085 1088.